FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer By Ogkologos - September 19, 2025 451 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in... July 16, 2025 FDA Approves Enzalutamide for Non-Metastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence December 15, 2023 Erdafitinib Prolongs Survival in Patients with Metastatic Urothelial Carcinoma and FGFR... November 3, 2023 First targeted treatment approved for advanced prostate cancer on NHS in... October 13, 2021 Load more HOT NEWS A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials Understanding FDA Emergency Use Authorization FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive Stage Small Cell... Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma
